DAREON™-7

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

IDENTIFIER (ClinicalTrials.gov): NCT06132113

DRUG/TREATMENT: BI 764532, Carboplatin, Etoposide, Cisplatin

PHASE: 1

STATUS: Recruiting

SPONSOR: Boehringer Ingelheim

DESCRIPTION:

This study is open to adults aged 18 and older or above legal age who have a specific type of advanced neuroendocrine cancer (NEC). Their tumours must be positive for a marker called DLL3.

The purpose of this study is to test a medicine called BI 764532 in addition to chemotherapy. The study has 2 parts. Part A of this study aims to find out the highest dose of BI 764532 that people can tolerate in addition to chemotherapy. 

The purpose of Part B is to find out how well people can tolerate BI 764532 in combination with different chemotherapies. Researchers also want to find out whether BI 764532 in combination with chemotherapy helps people with NEC.  Participants get different doses of BI 764532 as an infusion into a vein.

In addition, they get platinum-based chemotherapy as infusions into a vein. Participants can continue treatment up to 3 years if they benefit from treatment and can tolerate it.

Participants visit their doctors regularly. During these visits, the doctors collect information about participants' health and take note of any unwanted effects. Doctors also regularly check the size of the tumour.

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.

CONTACT: 

Boehringer Ingelheim

EMAIL: clintriage.rdg@boehringer-ingelheim.com

PHONE: 1-800-243-0127

This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

OTHER HELPFUL RESOURCES: